Evidence map›Paper›PMID 23506874›Full record

ReviewMolecular aspects of medicine

Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications.

David E Smith, Benjamin Clémençon, Matthias A Hediger

Open access · greenAbstract readReview
In one paragraph

Review in Molecular aspects of medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 165 papers.

0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

165 citing papers in PubMed, 313 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Uracil-Peptide-Pyrene Conjugates as CuChembiochem : a European journal of chemical biology · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Human Body Malodor and Deodorants: The Present and the Future.International journal of molecular sciences · 2025
    Review
  18. Review
  19. Article
  20. Review

105 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

David E SmithDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA. smithb@umich.edu
Benjamin Clémençon
Matthias A Hediger
University of Bern · CHUniversity of Michigan–Ann Arbor · US

Funding

Role of PEPT2 in Peptide/Mimetic Disposition-DynamicsR01GM035498 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SMITH, DAVID E · 1988 to 2013
$3.7M
NIGMS NIH HHS R01 GM035498NIGMS NIH HHS R01-GM035498
6 · The paper itself

Abstract

Mammalian members of the proton-coupled oligopeptide transporter family (SLC15) are integral membrane proteins that mediate the cellular uptake of di/tripeptides and peptide-like drugs. The driving force for uphill electrogenic symport is the chemical gradient and membrane potential which favors proton uptake into the cell along with the peptide/mimetic substrate. The peptide transporters are responsible for the absorption and conservation of dietary protein digestion products in the intestine and kidney, respectively, and in maintaining homeostasis of neuropeptides in the brain. They are also responsible for the absorption and disposition of a number of pharmacologically important compounds including some aminocephalosporins, angiotensin-converting enzyme inhibitors, antiviral prodrugs, and others. In this review, we provide updated information on the structure-function of PepT1 (SLC15A1), PepT2 (SLC15A2), PhT1 (SLC15A4) and PhT2 (SLC15A3), and their expression and localization in key tissues. Moreover, mammalian peptide transporters are discussed in regard to pharmacogenomic and regulatory implications on host pharmacology and disease, and as potential targets for drug delivery. Significant emphasis is placed on the evolving role of these peptide transporters as elucidated by studies using genetically modified animals. Whenever possible, the relevance of drug-drug interactions and regulatory mechanisms are evaluated using in vivo studies.

Indexed as

Genetic VariationModels, MolecularProtein ConformationAmino Acid SequenceAnimalsHumansMiceMice, KnockoutModels, BiologicalMolecular Sequence DataMultigene FamilyPeptide Transporter 1PharmacogeneticsProtein Interaction MapsSequence AlignmentSymportersPeptide Transporter 1SLC15A1 protein, humanSymporters

Identifiers

PMID23506874
PMCPMC3602806
OpenAlexW2003572328

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.